ResMed Inc. $RMD Shares Purchased by Principal Financial Group Inc.

Posted by Stanley Muller on Jul 19th, 2026

Principal Financial Group Inc. boosted its stake in ResMed Inc. (NYSE:RMD – Free Report) by 4.0% during the first quarter, Holdings Channel.com reports. The institutional investor owned 187,466 shares of the medical equipment provider’s stock after acquiring an additional 7,197 shares during the period. Principal Financial Group Inc.’s holdings in ResMed were worth $42,082,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of RMD. Imprint Wealth LLC purchased a new position in ResMed during the third quarter worth $26,000. WFA of San Diego LLC purchased a new stake in shares of ResMed in the second quarter valued at $26,000. International Assets Investment Management LLC purchased a new stake in shares of ResMed in the fourth quarter valued at $25,000. ORG Partners LLC boosted its stake in shares of ResMed by 181.6% during the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 69 shares during the last quarter. Finally, Sunbelt Securities Inc. acquired a new stake in shares of ResMed during the third quarter valued at $31,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Stock Performance

ResMed stock opened at $198.86 on Friday. The company has a market cap of $28.85 billion, a price-to-earnings ratio of 19.18, a price-to-earnings-growth ratio of 1.19 and a beta of 0.78. ResMed Inc. has a 12 month low of $180.26 and a 12 month high of $293.81. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. The stock’s 50-day moving average is $199.40 and its 200-day moving average is $226.64.

ResMed (NYSE:RMD – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.07. The business had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.42 billion. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The company’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.37 EPS. Equities analysts anticipate that ResMed Inc. will post 11.13 earnings per share for the current year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 1.2%. The ex-dividend date was Thursday, May 14th. ResMed’s payout ratio is currently 23.14%.

Insider Transactions at ResMed

In other news, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total value of $1,090,783.05. Following the completion of the sale, the chief executive officer owned 466,223 shares of the company’s stock, valued at $101,893,036.65. This represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 14,973 shares of company stock worth $3,096,067 in the last ninety days. 0.65% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Evercore set a $255.00 target price on shares of ResMed and gave the company an “outperform” rating in a research note on Monday, April 13th. Weiss Ratings cut shares of ResMed from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Citigroup reiterated a “neutral” rating and set a $235.00 price target (down from $270.00) on shares of ResMed in a report on Sunday, July 12th. JPMorgan Chase & Co. initiated coverage on shares of ResMed in a research report on Wednesday, April 15th. They issued an “overweight” rating for the company. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of ResMed in a research note on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, ResMed currently has a consensus rating of “Moderate Buy” and a consensus price target of $250.00.

Check Out Our Latest Analysis on RMD

ResMed Profile

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.